Roger W. Byhardt - Concepedia

Author

Roger W. Byhardt

Also Known As

Charles Scott, R BYHARDT, R Byhardt, R W Byhardt, R. Byhardt, R. W. Byhardt, R.W Byhardt, R.W. Byhardt, ROGER W. BYHARDT, Roger Byhardt

234

Publications

19K

Citations

H-Index

Concepts

All Affiliations

Medical College of Wisconsin RTOG Foundation The University of Texas MD Anderson Cancer Center Fox Chase Cancer Center Radiation Oncology Associates

About

Roger W. Byhardt is an author at Medical College of Wisconsin specializing in oncology, radiation oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	45	89	6.8K
2	Health Sciences	34	57	4.4K
3	Cell Biology	3	3	188
4	Engineering	1	1	133
5	Biostatistics	1	1	86

Roger W. Byhardt

125

Publications

17.9K

Citations

H-Index

Page 1

	Year	Citations
Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials Laurie E. Gaspar, Charles Scott, Marvin Rotman, International Journal of Radiation OncologyBiologyPhysics	1997	2.5K
Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the Esophagus Arnold Herskovic, Karen Martz, Muhyi Al‐Sarraf, New England Journal of Medicine	1992	2.1K
Chemoradiotherapy of Locally Advanced Esophageal Cancer Jay S. Cooper, Matthew Guo, Arnold Herskovic, JAMA	1999	1.9K
Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. Muhyi Al‐Sarraf, Karen Martz, Arnold Herskovic, Journal of Clinical Oncology	1997	743
Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary Results of a Phase III Trial in Regionally Advanced, Unresectable Non-Small-Cell Lung Cancer W. T. Sause, Charles Scott, S. Taylor, JNCI Journal of the National Cancer Institute	1995	714
Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer William T. Sause, Patricia Kolesar, Samuel G. Taylor, CHEST Journal Final ResultsMedicineCancer ManagementPhase Iii TrialBronchial Neoplasm	2000	630
Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. Miljenko V. Pilepich, Richard Caplan, Roger W. Byhardt, Journal of Clinical Oncology	1997	609
A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. James D. Cox, N. Azarnia, Roger W. Byhardt, Journal of Clinical Oncology Surgical OncologyTreatment VerificationRadiation MedicineOncologyMetronomic Therapy	1990	471
Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410 Walter J. Curran, Charles Scott, Corey J. Langer, Lung Cancer Health SciencesRadiation TherapyMedicineClinical Radiation OncologyOncology	2000	300
Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. William Tester, Richard Caplan, John Heaney, Journal of Clinical Oncology	1996	276

Page 1